News
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...
Stocktwits on MSN4d
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZenecaPfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...
The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...
The Nobel Prize winning scientist behind mRNA vaccine technology has attacked the US health secretary’s plan to effectively ...
Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in ...
2don MSN
RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...
Health Secretary Robert F. Kennedy Jr.'s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...
On Tuesday, the US Department of Health and Human Services disclosed the end of funding for 22 mRNA vaccine projects — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback